Financial Ratios Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Equities
002603
CNE1000015S0
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.72 CNY | -0.45% |
|
0.00% | +3.81% |
| 01-07 | Chinese Drug Regulator Accepts Yiling Pharmaceutical's Application for Qilong Dingchuan Tablets | MT |
| 01-07 | Yiling Pharmaceutical Unit Gets Nod to Market Dapagliflozin | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 8.67 | 7.78 | 12.2 | 6.05 | -3.45 | |||||
Return on Total Capital | 10.37 | 9.74 | 16.14 | 8.18 | -4.53 | |||||
Return On Equity % | 14.4 | 14.91 | 23.57 | 12.02 | -6.79 | |||||
Return on Common Equity | 14.45 | 14.94 | 23.62 | 12.08 | -6.69 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 64.42 | 63.43 | 63.64 | 57.03 | 46.47 | |||||
SG&A Margin | 39.12 | 38.85 | 30.89 | 31.95 | 45.06 | |||||
EBITDA Margin % | 19.25 | 18.44 | 26.25 | 20.86 | -3.63 | |||||
EBITA Margin % | 16.53 | 15.3 | 23.05 | 15.93 | -12.34 | |||||
EBIT Margin % | 16.24 | 15.01 | 22.77 | 15.63 | -12.85 | |||||
Income From Continuing Operations Margin % | 13.83 | 13.26 | 18.81 | 13.03 | -11.27 | |||||
Net Income Margin % | 13.88 | 13.28 | 18.84 | 13.11 | -11.12 | |||||
Net Avail. For Common Margin % | 13.88 | 13.28 | 18.84 | 13.11 | -11.12 | |||||
Normalized Net Income Margin | 10.27 | 9.29 | 14.17 | 9.84 | -7.71 | |||||
Levered Free Cash Flow Margin | 15.58 | 2.49 | 29.28 | 1.01 | 10.08 | |||||
Unlevered Free Cash Flow Margin | 15.61 | 2.7 | 29.45 | 1.25 | 10.36 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.85 | 0.83 | 0.86 | 0.62 | 0.43 | |||||
Fixed Assets Turnover | 2.38 | 2.01 | 2.09 | 1.52 | 0.89 | |||||
Receivables Turnover (Average Receivables) | 4.24 | 4.91 | 5.52 | 4.32 | 3.26 | |||||
Inventory Turnover (Average Inventory) | 2.23 | 2.27 | 2.47 | 1.98 | 1.66 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.44 | 1.89 | 1.5 | 1.47 | 1.66 | |||||
Quick Ratio | 1.49 | 1.16 | 0.95 | 0.84 | 0.91 | |||||
Operating Cash Flow to Current Liabilities | 0.71 | 0.18 | 0.72 | 0.03 | 0.23 | |||||
Days Sales Outstanding (Average Receivables) | 86.33 | 74.32 | 66.16 | 84.47 | 112.14 | |||||
Days Outstanding Inventory (Average Inventory) | 164.1 | 160.47 | 147.98 | 184.41 | 220.73 | |||||
Average Days Payable Outstanding | 89.06 | 135.21 | 136.98 | 183.86 | 312.91 | |||||
Cash Conversion Cycle (Average Days) | 161.38 | 99.57 | 77.16 | 85.02 | 19.96 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 3.03 | 13.55 | 7.97 | 12.41 | 0.26 | |||||
Total Debt / Total Capital | 2.94 | 11.93 | 7.38 | 11.04 | 0.26 | |||||
LT Debt/Equity | - | 5.65 | 1.97 | 5.35 | 0.18 | |||||
Long-Term Debt / Total Capital | - | 4.98 | 1.82 | 4.76 | 0.18 | |||||
Total Liabilities / Total Assets | 22.35 | 29.7 | 33.09 | 32.64 | 23.4 | |||||
EBIT / Interest Expense | 370.77 | 44.7 | 84.43 | 41.46 | -28.86 | |||||
EBITDA / Interest Expense | 439.49 | 55.23 | 97.66 | 55.53 | -7.8 | |||||
(EBITDA - Capex) / Interest Expense | 141.91 | 35.4 | 91.33 | 47.53 | -17.82 | |||||
Total Debt / EBITDA | 0.16 | 0.65 | 0.26 | 0.66 | -0.12 | |||||
Net Debt / EBITDA | -0.76 | 0.1 | -0.47 | 0.13 | 3.65 | |||||
Total Debt / (EBITDA - Capex) | 0.49 | 1.02 | 0.28 | 0.77 | -0.05 | |||||
Net Debt / (EBITDA - Capex) | -2.35 | 0.15 | -0.5 | 0.15 | 1.6 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 50.76 | 15.19 | 23.88 | -17.67 | -36.88 | |||||
Gross Profit, 1 Yr. Growth % | 52.13 | 13.42 | 24.3 | -26.23 | -48.57 | |||||
EBITDA, 1 Yr. Growth % | 85.68 | 10.12 | 75.79 | -34.67 | -110.98 | |||||
EBITA, 1 Yr. Growth % | 117.12 | 6.36 | 86 | -43.18 | -148.8 | |||||
EBIT, 1 Yr. Growth % | 119.16 | 6.48 | 87.88 | -43.48 | -151.9 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 101.47 | 10.43 | 75.67 | -42.98 | -154.61 | |||||
Net Income, 1 Yr. Growth % | 100.95 | 10.27 | 75.75 | -42.76 | -153.57 | |||||
Normalized Net Income, 1 Yr. Growth % | 111.43 | 4.21 | 88.88 | -41.91 | -149.51 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 100 | 10.27 | 75.75 | -42.76 | -153.58 | |||||
Accounts Receivable, 1 Yr. Growth % | -26.3 | 34.44 | -7.77 | 19.23 | -46.46 | |||||
Inventory, 1 Yr. Growth % | 29.34 | 5.85 | 20.87 | 21.61 | -28.97 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 40.93 | 33.5 | 8.19 | 17.37 | -0.8 | |||||
Total Assets, 1 Yr. Growth % | 26.72 | 12.29 | 26.59 | 3.91 | -21.56 | |||||
Tangible Book Value, 1 Yr. Growth % | 12.83 | -0.36 | 21.4 | 3.75 | -12.08 | |||||
Common Equity, 1 Yr. Growth % | 12.27 | 1.68 | 20.54 | 4.73 | -10.71 | |||||
Cash From Operations, 1 Yr. Growth % | 2.2K | -66.67 | 559.69 | -95.54 | 293.04 | |||||
Capital Expenditures, 1 Yr. Growth % | 151.92 | -41.16 | -68.23 | 45.26 | -6.58 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -425.7 | -81.53 | 1.36K | -97.16 | 540.18 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -426.31 | -80.07 | 1.25K | -96.51 | 431.77 | |||||
Dividend Per Share, 1 Yr. Growth % | 399.86 | -58 | 66.67 | -40 | - | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 35.06 | 31.78 | 19.46 | 0.99 | -27.91 | |||||
Gross Profit, 2 Yr. CAGR % | 33.42 | 31.36 | 18.74 | -4.24 | -38.4 | |||||
EBITDA, 2 Yr. CAGR % | 34.75 | 43.16 | 39.33 | 7.24 | -73.21 | |||||
EBITA, 2 Yr. CAGR % | 44.38 | 52.16 | 40.89 | 2.88 | -47.3 | |||||
EBIT, 2 Yr. CAGR % | 45.04 | 52.76 | 41.44 | 3.05 | -45.84 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 43.14 | 49.16 | 39.28 | 0.1 | -44.2 | |||||
Net Income, 2 Yr. CAGR % | 42.61 | 48.85 | 39.21 | 0.32 | -44.62 | |||||
Normalized Net Income, 2 Yr. CAGR % | 42.65 | 48.44 | 40.3 | 3.9 | -46.37 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 42.84 | 48.6 | 39.21 | 0.32 | -44.62 | |||||
Accounts Receivable, 2 Yr. CAGR % | -4.78 | -0.46 | 11.35 | 4.87 | -20.1 | |||||
Inventory, 2 Yr. CAGR % | 15.94 | 17.01 | 13.11 | 21.24 | -7.06 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 22.75 | 37.17 | 20.18 | 12.68 | 7.9 | |||||
Total Assets, 2 Yr. CAGR % | 15.89 | 19.29 | 19.23 | 14.71 | -9.72 | |||||
Tangible Book Value, 2 Yr. CAGR % | 8.2 | 6.03 | 9.98 | 12.23 | -4.49 | |||||
Common Equity, 2 Yr. CAGR % | 8.61 | 6.84 | 10.71 | 12.36 | -3.3 | |||||
Cash From Operations, 2 Yr. CAGR % | 368.17 | 176.96 | 48.28 | -45.77 | -58.14 | |||||
Capital Expenditures, 2 Yr. CAGR % | 147.27 | 21.75 | -56.77 | -32.07 | 16.49 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 120.12 | -22.56 | 64.04 | -35.65 | -57.71 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 120.32 | -19.36 | 64.1 | -31.38 | -57.25 | |||||
Dividend Per Share, 2 Yr. CAGR % | 216.29 | 44.89 | -16.33 | 0 | - | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 29.1 | 28.08 | 29.1 | 5.52 | -13.65 | |||||
Gross Profit, 3 Yr. CAGR % | 26.77 | 26.39 | 28.96 | 1.32 | -22.16 | |||||
EBITDA, 3 Yr. CAGR % | 26.11 | 26.07 | 53.45 | 8.29 | -49.82 | |||||
EBITA, 3 Yr. CAGR % | 32.98 | 30.51 | 62.88 | 4.14 | -19.72 | |||||
EBIT, 3 Yr. CAGR % | 33.59 | 30.84 | 63.67 | 4.18 | -18.01 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 31.3 | 31.28 | 57.52 | 3.43 | -18.21 | |||||
Net Income, 3 Yr. CAGR % | 31.11 | 30.89 | 57.33 | 3.53 | -18.61 | |||||
Normalized Net Income, 3 Yr. CAGR % | 32.38 | 28.47 | 60.85 | 4 | -18.85 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 31.37 | 31.09 | 57.14 | 3.53 | -18.61 | |||||
Accounts Receivable, 3 Yr. CAGR % | 13.02 | 6.83 | -2.96 | 13.92 | -16.19 | |||||
Inventory, 3 Yr. CAGR % | 13.69 | 12.47 | 18.28 | 15.87 | 1.45 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 12.78 | 26.23 | 26.73 | 19.24 | 8 | |||||
Total Assets, 3 Yr. CAGR % | 13.37 | 14.68 | 21.67 | 13.89 | 1.06 | |||||
Tangible Book Value, 3 Yr. CAGR % | 7.69 | 5.27 | 10.92 | 7.86 | 3.46 | |||||
Common Equity, 3 Yr. CAGR % | 7.85 | 6.25 | 11.23 | 8.68 | 4.07 | |||||
Cash From Operations, 3 Yr. CAGR % | 140.06 | 94.04 | 269.87 | -53.89 | 4.94 | |||||
Capital Expenditures, 3 Yr. CAGR % | 85.16 | 53.23 | -22.2 | -35.25 | -24.46 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 136.23 | -3.73 | 105.96 | -57.55 | 37.61 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 141.18 | -1.1 | 106.36 | -54.56 | 35.17 | |||||
Dividend Per Share, 3 Yr. CAGR % | 115.47 | 61.36 | 51.81 | -25.11 | - | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 22.49 | 21.32 | 25.16 | 16.47 | 2.26 | |||||
Gross Profit, 5 Yr. CAGR % | 22.87 | 20.11 | 23.49 | 13.11 | -4.04 | |||||
EBITDA, 5 Yr. CAGR % | 21.51 | 17.38 | 31.3 | 18.24 | -23.63 | |||||
EBITA, 5 Yr. CAGR % | 23.38 | 19.39 | 36.16 | 18.74 | 3.75 | |||||
EBIT, 5 Yr. CAGR % | 23.64 | 19.66 | 36.68 | 18.92 | 5.16 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 23.27 | 20.63 | 34.43 | 17.79 | 4.01 | |||||
Net Income, 5 Yr. CAGR % | 23.14 | 20.33 | 34.29 | 17.68 | 3.62 | |||||
Normalized Net Income, 5 Yr. CAGR % | 23.38 | 19.19 | 35.49 | 18.02 | 3.32 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 21.84 | 19.1 | 34.48 | 17.78 | 3.55 | |||||
Accounts Receivable, 5 Yr. CAGR % | 27.37 | 23.79 | 12.35 | 6.04 | -10.22 | |||||
Inventory, 5 Yr. CAGR % | 8.77 | 12.52 | 13.45 | 15.9 | 7.41 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 9.55 | 13.78 | 15.68 | 20.63 | 18.84 | |||||
Total Assets, 5 Yr. CAGR % | 15.03 | 15.58 | 15.68 | 14.69 | 7.99 | |||||
Tangible Book Value, 5 Yr. CAGR % | 13.62 | 11.1 | 8.6 | 8 | 4.48 | |||||
Common Equity, 5 Yr. CAGR % | 13.12 | 11.25 | 8.98 | 8.65 | 5.17 | |||||
Cash From Operations, 5 Yr. CAGR % | 64.45 | -3.79 | 97.98 | 16.52 | 54.72 | |||||
Capital Expenditures, 5 Yr. CAGR % | 19.06 | 12.5 | 3.48 | 10.67 | -8.57 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 108.21 | 11.86 | 104.03 | -18.06 | 9.34 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 104.82 | 12.86 | 106.75 | -14.55 | 9.94 | |||||
Dividend Per Share, 5 Yr. CAGR % | 58.5 | 33.26 | 47.59 | 33.26 | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















